Nautilus Biotechnology, Inc. — Form D/A
Nautilus Biotechnology, Inc. of San Carlos, CA, a company, filed a Form D amendment with the SEC on 2020-05-28. The offering totals $76.1M, of which $76.1M was reported sold. Industry: Other.
Offering
- Filed: 2020-05-28
- Form: D/A
- Accession: 0001741638-20-000003
- Industry: Other
- Exemptions: 06b
- Total offering: $76.1M
- Amount sold: $76.1M
- Remaining: $12
- Investors: 19
- Date of first sale: 2020-04-08
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-365575
Issuer
- Name: Nautilus Biotechnology, Inc.
- CIK: 0001741638
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: 201 Industrial Rd, STE 310, San Carlos, CA, 94070
- Phone: (206) 333-2001
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Parag Mallick | Director | Seattle, WA |
| Stuart Nagae | Director | Seattle, WA |
| Farzad Nazem | Director | Seattle, WA |
| Vijay Pande | Director | Richmond, CA |
| Sujal Patel | Director | Seattle, WA |
| Matthew Posard | Director | Waltham, MA |
| Sujal Patel | Executive Officer | Seattle, WA |
Other filings by this issuer (2)
More